
News|Articles|May 9, 2025
Specialty Pharmacy at a Crossroads, Say Attendees at Asembia’s AXS25 Summit
Specialty pharmacy experts and key opinion leaders gathered at Asembia’s AXS25 Summit and discussed critical insights in interviews with Pharmacy Times®.
Advertisement
Advertisement
Specialty pharmacy is changing rapidly. A field once restricted to some of the more complex and difficult-to-treat conditions in the health care landscape, specialty pharmacy is facing a series of transformative trends that are set to reshape the industry. At Asembia’s AXS25 Summit, which took place from April 27 to May 1 in Las Vegas, Nevada, experts on the ground discussed the future of the field and what comes next as groundbreaking therapies emerge and policy shifts occur.
Related to this article

With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.

A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.

At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.

Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.

Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.

Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.

Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
Advertisement
Advertisement

